Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Georgia Health Sciences University
mi
from
Augusta, GA
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Georgia Health Sciences University
mi
from
Augusta, GA
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Clarian North Hospital
mi
from
Carmel, IN
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Clarian North Hospital
mi
from
Carmel, IN
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Kentuckiana Pulmonary Associates
mi
from
Louisville, KY
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Kentuckiana Pulmonary Associates
mi
from
Louisville, KY
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
LSU Health Science Center - New Orleans
mi
from
New Orleans, LA
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
LSU Health Science Center - New Orleans
mi
from
New Orleans, LA
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Tufts Medical Center
mi
from
Boston, MA
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Boston University School of Medicine / Boston University Medical Center
mi
from
Boston, MA
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Boston University School of Medicine / Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Massachusetts General Hospital-Pulmonary Critical Care Unit
mi
from
Boston, MA
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Massachusetts General Hospital-Pulmonary Critical Care Unit
mi
from
Boston, MA
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
University of Michigan
mi
from
Ann Arbor, MI
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Henry Ford Hospital
mi
from
Detroit, MI
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Newark Beth Isreal Medical Center-Department of Pulmonary Medicine
mi
from
Newark, NJ
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Newark Beth Isreal Medical Center-Department of Pulmonary Medicine
mi
from
Newark, NJ
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Columbia University Medical Center, Pediatric Cardiology
mi
from
New York, NY
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Columbia University Medical Center, Pediatric Cardiology
mi
from
New York, NY
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
University of Cincinnati
mi
from
Cincinnati, OH
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
The Lindner Clinical Trial Center
mi
from
Cincinnati, OH
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
The Lindner Clinical Trial Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Oregon Pulmonary Associates, PC
mi
from
Portland, OR
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Oregon Pulmonary Associates, PC
mi
from
Portland, OR
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Central Bucks Specialists
mi
from
Doylestown, PA
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Central Bucks Specialists
mi
from
Doylestown, PA
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Penn Presbyterian Medical Center
mi
from
Philadelphia, PA
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Penn Presbyterian Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Vanderbilt Medical Center
mi
from
Nashville, TN
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Vanderbilt Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
UT Southwestern Medical Center at Dallas
mi
from
Dallas, TX
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
UT Southwestern Medical Center at Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Baylor College of Medicine
mi
from
Houston, TX
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
University of Texas-Houston Health Center Department of Pulmonary & Critical Care
mi
from
Houston, TX
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
University of Texas-Houston Health Center Department of Pulmonary & Critical Care
mi
from
Houston, TX
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
University of Wisconsin Hospital-Department of Medicine
mi
from
Madison, WI
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
University of Wisconsin Hospital-Department of Medicine
mi
from
Madison, WI
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
St. Luke's Medical Center
mi
from
Milwaukee, WI
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Beaumont Hospital
mi
from
Troy, MI
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Beaumont Hospital
mi
from
Troy, MI
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Montefiore Medical Center-Weiler Division
mi
from
Bronx, NY
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Montefiore Medical Center-Weiler Division
mi
from
Bronx, NY
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Froedtert Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Froedtert Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Centro de Investigacion y Prevencion Cardiovascular (CIPREC)
mi
from
Buenos Aires,
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Centro de Investigacion y Prevencion Cardiovascular (CIPREC)
mi
from
Buenos Aires,
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
University of Arizona Clinical and Translational Science (CATS) Research Center
mi
from
Tucson, AZ
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
University of Arizona Clinical and Translational Science (CATS) Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Georgia Clinical Research
mi
from
Austell, GA
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Georgia Clinical Research
mi
from
Austell, GA
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/13/2017
Ohio State University Medical Center
mi
from
Columbus, OH
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/13/2017
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study
The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study
Status: Enrolling
Updated:  12/13/2017
University of Mississippi Medical Center General Medicine/Hypertension and Family Medicine Clinics
mi
from
Jackson, MS
The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study
The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study
Status: Enrolling
Updated: 12/13/2017
University of Mississippi Medical Center General Medicine/Hypertension and Family Medicine Clinics
mi
from
Jackson, MS
Click here to add this to my saved trials
Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  12/19/2017
Aerie Pharmaceuticals
mi
from
Bedminster, NJ
Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 12/19/2017
Aerie Pharmaceuticals
mi
from
Bedminster, NJ
Click here to add this to my saved trials
Morning Versus Evening Dosing of Antihypertensive Medications: A Pilot Study to Assess Feasibility and Efficacy
Evening Dosing of Antihypertensive Medications in Chronic Kidney Disease Patients - A Pilot Study
Status: Enrolling
Updated:  12/27/2017
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Morning Versus Evening Dosing of Antihypertensive Medications: A Pilot Study to Assess Feasibility and Efficacy
Evening Dosing of Antihypertensive Medications in Chronic Kidney Disease Patients - A Pilot Study
Status: Enrolling
Updated: 12/27/2017
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Treatment of Masked Hypertension
Treatment of Masked Hypertension
Status: Enrolling
Updated:  12/27/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Treatment of Masked Hypertension
Treatment of Masked Hypertension
Status: Enrolling
Updated: 12/27/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated:  12/27/2017
205.452.01107 Boehringer Ingelheim Investigational Site
mi
from
Athens, AL
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated: 12/27/2017
205.452.01107 Boehringer Ingelheim Investigational Site
mi
from
Athens, AL
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated:  12/27/2017
1245.25.10037 Boehringer Ingelheim Investigational Site
mi
from
Huntsville, AL
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated: 12/27/2017
1245.25.10037 Boehringer Ingelheim Investigational Site
mi
from
Huntsville, AL
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated:  12/27/2017
205.452.01244 Boehringer Ingelheim Investigational Site
mi
from
Mobile, AL
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated: 12/27/2017
205.452.01244 Boehringer Ingelheim Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated:  12/27/2017
1301.1.5727 Boehringer Ingelheim Investigational Site
mi
from
Glendale, AZ
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated: 12/27/2017
1301.1.5727 Boehringer Ingelheim Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated:  12/27/2017
502.476.066 Boehringer Ingelheim Investigational Site
mi
from
Carlisle, AR
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated: 12/27/2017
502.476.066 Boehringer Ingelheim Investigational Site
mi
from
Carlisle, AR
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated:  12/27/2017
502.476.067 Boehringer Ingelheim Investigational Site
mi
from
Buena Park, CA
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated: 12/27/2017
502.476.067 Boehringer Ingelheim Investigational Site
mi
from
Buena Park, CA
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated:  12/27/2017
205.452.01038 Boehringer Ingelheim Investigational Site
mi
from
Encinitas, CA
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated: 12/27/2017
205.452.01038 Boehringer Ingelheim Investigational Site
mi
from
Encinitas, CA
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated:  12/27/2017
1218.61.01014 Boehringer Ingelheim Investigational Site
mi
from
Greenbrae, CA
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated: 12/27/2017
1218.61.01014 Boehringer Ingelheim Investigational Site
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated:  12/27/2017
1199.14.1181 Boehringer Ingelheim Investigational Site
mi
from
Long Beach, CA
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated: 12/27/2017
1199.14.1181 Boehringer Ingelheim Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials